The implantation of a second-generation drug-eluting stent fully covering a coronary artery aneurysm and stenosis lesion was found to be safe and effective.
Increasing burden of atrial fibrillation in HFpEF was found to be associated with lower left atrial compliance and mechanics.
The addition of evinacumab to stable lipid-lowering therapy was found to reduce levels of LDL-C in patients with homozygous familial hypercholesterolemia.
A newly developed prognostic metabolite score was found to be useful in distinguishing heart failure with midrange vs preserved or reduced ejection fraction.
RV dysfunction and impaired RV-pulmonary artery coupling in patients with acutely decompensated heart failure were found to be associated with greater severity and lower resolution of pulmonary congestion.
Evolocumab treatment in addition to statin therapy was found to lower cardiovascular risk in patients with metabolic syndrome and stable atherosclerotic cardiovascular disease.
Serum levels of magnesium may not be associated with arrhythmia burden in older adults.
Loading of third-generation P2Y12 inhibitors before primary percutaneous coronary intervention for STEMI was associated with a reduction in the index of microcirculatory resistance.
Levels of a set of circulating biomarkers were found to be elevated in patients with HFpEF.
Copeptin combined with hs-cTnT was found to be effective for instant rule-out of NSTEMI.
